EORTC research presented at ESMO 2026
22 Oct 2026
EORTC will showcase a strong portfolio of oral and poster presentations at the ESMO Congress 2026, taking place in Madrid, Spain, from 23-27 October 2026. Oral presentations will feature results from clinical and translational research studies, while a broad poster programme will highlight ongoing and planned trials, methodological research, patient involvement initiatives, and quality of life research, reflecting the breadth of EORTC’s multidisciplinary cancer research programme.
EORTC ABSTRACTS |
|
ORAL PRESENTATIONS |
|
| INFORMED CONSENT MATERIALS THROUGH THE EYES OF PATIENTS: A QUALITATIVE ANALYSIS OF EORTC PATIENT REVIEWS Iryna Shakhnenko, Belgium | Saturday, 24 October 2026, 15:47 – 15:52 Type: Rapid Oral Session Location: Seville Auditorium – NCC Abstract number: 3324RO |
| COMPARABLE SWALLOWING FUNCTION AT 12 MONTHS BUT DIVERGENT TOXICITY PROFILES WITH TOS VERSUS DO-IMRT IN EARLY-STAGE OROPHARYNGEAL, SUPRAGLOTTIC AND HYPOPHARYNGEAL CARCINOMA: PRIMARY RESULTS OF THE PHASE III EORTC 1420 BEST-OF TRIAL Christian Simon, Switzerland | Sunday, 25 October 2026, 09:28 – 09:38 Type: Proffered Paper Session Location: Madrid Auditorium – Hall 4 Abstract number: 1535O |
| FINAL ANALYSIS OF ADJUVANT PEMBROLIZUMAB (PEMBRO) IN RESECTED EARLY-STAGE NON-SMALL-CELL LUNG CANCER (NSCLC): PHASE 3 PEARLS/KEYNOTE-091 STUDY Mary O’Brien, United Kingdom | Monday, 26 October 2026, 15:43 – 15:53 Type: Proffered Paper Session Location: Alicante Auditorium – Hall 6 Abstract number: 2511O |
POSTERS |
|
| IMPACT OF ENZALUTAMIDE-RELATED DRUG–DRUG INTERACTIONS ON ADVERSE EVENTS IN THE EORTC 1333GUCG PEACE-3 TRIAL Mehdi Bsilat, Belgium | Friday, 23 October 2026, 15:15 – 16:00 Type: Poster Session Abstract number: 2245P |
| CHARACTERIZATION OF THE MOLECULAR AND IMMUNE MICRO ENVIRONMENT LANDSCAPE OF SYNCHRONOUS VS METACHRONOUS RCC: AN IMMUCAN PROJECT Marie Morfouace, France | Friday, 23 October 2026, 15:15 – 16:00 Type: Poster Session Abstract number: 3600P |
| ADJUVANT TEBENTAFUSP (IMCGP100) VERSUS OBSERVATION IN HLA-A*02:01 POSITIVE PATIENTS FOLLOWING DEFINITIVE TREATMENT OF HIGH-RISK UVEAL MELANOMA: AN EORTC RANDOMIZED PHASE III STUDY Paul Nathan, United Kingdom | Saturday, 24 October 2026, 12:00 – 12:45 Type: Trial in Progress Abstract number: 2139TiP |
| ≥4 POSITIVE NODES IDENTIFY A POPULATION ENRICHED FOR ctDNA-GUIDED ADJUVANT TREATMENT ESCALATION IN ER+/HER2− EARLY BREAST CANCER Teck Long King, Belgium | Saturday, 24 October 2026, 12:00 – 12:45 Type: Poster Session Abstract number: 583P |
| ANALYSIS AND REPORTING OF PFS IN CONTEMPORARY PHASE 2-3 TRIALS IN SOLID ONCOLOGY: A SYSTEMATIC REVIEW Annemiek Van Ommen-Nijhof, Netherlands | Sunday, 25 October 2026, 12:00 – 12:45 Type: Poster Session Abstract number: 3332P |
| CURRENT PRACTICE CONSIDERATIONS FOR BRAIN METASTASES IN GASTROESOPHAGEAL CANCER PATIENTS: AN INTERNATIONAL EORTC SURVEY Hannah C. Puhr, Austria | Type: E-Poster Abstract number: 749eP |
| COVERAGE OF TREATMENT-RELATED TOXICITIES BY EORTC QLQ-C30 AND QLQ-H&N43 IN HEAD AND NECK CANCER Myrto Moutafi, Greece | Type: E-Poster Abstract number: 1622eP |
| DIAGNOSIS, TREATMENT AND FOLLOW-UP PRACTICES FOR LOCALLY ADVANCED NASOPHARYNGEAL CANCER (NPC) IN NON-ENDEMIC REGIONS: AN EORTC LED SURVEY Alvina Vadassery, Belgium | Type: E-Poster Abstract number: 1623eP |
Related News
New European AI assistant to make patient experiences actionable for care and health systems
12 Nov 2026
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
